Metro International Biotech, LLC focuses on the therapeutic potential of nicotinamide adenine dinucleotide (NAD+), a crucial cofactor for cellular functions and energy production. Research indicates that NAD+ levels decline with age, which is associated with various health issues, including mitochondrial dysfunction and inflammation. The company is pioneering the development of NAD+ pharmaceuticals aimed at addressing these declines, particularly in the context of rare mitochondrial diseases. Their studies suggest that increasing NAD+ levels can enhance mitochondrial health by inducing mitochondrial biogenesis and activating key pathways involving sirtuins and PGC-1alpha, which are essential for maintaining metabolic functions across multiple organ systems.

The company's approach is grounded in preclinical evidence that supports the idea that boosting NAD+ can mitigate age-related and disease-related functional declines. By targeting the mechanisms that regulate NAD+ levels, Metro International Biotech aims to develop therapies that not only address the unmet medical needs associated with rare mitochondrial diseases but also promote overall health and longevity. Their research highlights the systemic effects of NAD+, emphasizing its role in regulating metabolism, neuroprotection, and stem cell rejuvenation, thereby positioning NAD+ modulation as a promising strategy for enhancing healthspan and lifespan.

United States

Metro International Biotech, LLC is a privately-owned clinical-stage pharmaceutical company that has established the most comprehensive portfolio of proprietary drugs for the treatment of various diseases.

Metro International Biotech, LLC

Company Details